Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells
S. A. Misek, P. A. Newbury, E. Chekalin, S. Paithankar, A. I. Doseff, B. Chen, K. A. Gallo, R. R. Neubig
This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.
bioRxiv · Mar 25, 2020Cancer Biology